Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck

Pioneer Natural Resources

Vanguard Small Cap Value ETF

Vanguard S&P Small-Cap 600 ETF

Generation X investors came of age in the dot-com boom when Microsoft and other tech titans hit new highs. Now, in 2020, it's happening again.

Generation X Investors: Deja Vu?

AmerisourceBergen

Aflac

AvalonBay Communities

Broadcom

Bristol-Myers

Bank of Nova Scotia

CVS Health

FLIR Systems

Federal Realty Investment Trust

General Dynamics

Intel

Reinsurance Group of America

Simon Property Group

STORE Capital

September 2020 Stocks - Financials, Real Estate, Industrials, IT And Pharma

British American Tobacco

Cardinal Health

Canadian Natural Resources

Chevron

Diageo

Enbridge

Pembina Pipeline

People's United Financial

Sanofi

AT&T

These Kiplinger "Top Dividend Stocks From Around The World" (a.k.a. the most reliable dividends on earth) are perfect for the dogcatcher process.

A 91 Kiplinger 'Most Reliable Dividend Stocks On Earth' September Update

AbbVie (ABBV) signs a collaboration agreement with China's I-Mab for developing/commercializing the latter's lemzoparlimab to address various cancer types.

AbbVie Partners With Chinese Biotech for Cancer Candidate

eBay

Gilead Sciences

General Mills

GlaxoSmithKline

H&R Block

Hormel Foods

Kimberly-Clark

Lockheed Martin

Lam Research

PepsiCo

Philip Morris

Roche Holding AG

Unilever

33 Dividend Stocks Fit For COVID-19 Times: A September Update

I-Mab

Shanghai's I-Mab out-licensed ex-China rights for lemzoparlimab, its anti-CD47 mAb, to AbbVie in a blockbuster $2 billion agreement.

Week In Review: I-Mab Partners CD47 With AbbVie In $2 Billion Deal

The deal could be the largest-ever out-licensing agreement by a Chinese biotech.

AbbVie Partners With I-Mab for Cancer Drug

Humira Battles: AbbVie's Upa Versus Gilead's Filgo-Redux

Medical Transcription Billing Corp 11 % Cum Red Perp Pfd Shs Series A

20 company dividend payments were received, increasing income by 32%, reversing the low income of July, making Q3 up 2.5% from April and May of Q2.

The Rose 89 Stock Portfolio August 2020 Update

Anthem

GATX

Ingredion

McKesson

Magna International

Science Applications International

Universal Health Services

ViacomCBS

Stocks have made a remarkable (and remarkably rapid) recovery from the 2020 bear market.

11 Best Value Stocks for This Overpriced Market

Walgreens

AbbVie, Cardinal Health, and Walgreens Boots Alliance are all showing growth, and each boasts a yield of at least 3.8%.

3 Ultra-High-Yield Medical Stocks That Aren't Done Growing Yet

AbbVie (NASDAQ: ABBV) shares are trading lower on Tuesday after the U.S. House of Representatives says it plans to subpoena the company over Humira and Imbruvica pricing after the company "repeatedly failed to comply with the Committee's requests.

Why AbbVie's Stock Is Trading Lower Today

A U.S. House panel investigating drug prices said it will subpoena AbbVie, which it says has failed to comply with requests for information over the past 18 months. ABBV stock fell.

House Panel Investigating Drug Prices To Subpoena AbbVie

The U.S. House Oversight Committee has decided to subpoena drugmaker Abbvie Inc to seek documents as part of its investigation into drug pricing practices.

U.S. House Oversight Committee to subpoena AbbVie in drug-pricing probe

It might not be a Dividend King, but AbbVie is no slacker when it comes to payments to its investors.

Forget Johnson & Johnson, AbbVie Is a Better Dividend Stock

AbbVie: Dividend Growth Stock Trading At A BIG Discount

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock?

AbbVie (ABBV) Down 2% Since Last Earnings Report: Can It Rebound?

Why I Bought AbbVie Despite 43% Appreciation This Year

JPMorgan Chase & Co

Earn some extra cash with these income-generating investments.

These 3 Dividend Stocks Could Bring You an Extra $100 a Month

Eli Lilly

Pfizer

If you had gone off the grid in early January with no communication and just came back, you would see all the market indexes making new highs, but the levels are close to when you left.

Why Dividend-Paying Big Drug Companies May Be the Best Stocks to Own Now

AbbVie (ABBV) files an application to the FDA, seeking its nod for a new indication of Rinvoq, which is active ankylosing spondylitis. The drug is already marketed to treat rheumatoid arthritis.

AbbVie Seeks FDA Approval for Rinvoq in Ankylosing Spondylitis

News for AbbVie Stock (ABBV)